Replies to post #25170 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 4Q21 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency)   
 Medical devices*  33%       +16%     
 Diagnostics       39%        +3%     
 Nutrition         18%        +6%     
 Drugs†            10%        +6% 

4Q21 COVID diagnostics sales were $2.3B, 51% of total 4Q21 diagnostics sales and 20% of total 4Q21 corporate sales.

58% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.

[DewDiligence]

ABT fell 6% cumulatively_on_Thu/Fri_due_to infant-formula recall:

https://finance.yahoo.com/news/abbott-voluntarily-recalls-powder-formulas-221100997.html

Although ABT’s PR was issued after the market close on Thursday, news of the recall was already on the internet during trading hours.

Although ABT says the effect of the recall will not be material to 1Q21 financial results and ABT has reiterated 2022 non-GAAP EPS guidance of $4.70+, the blow to ABT’s reputation as a quality vendor may linger. Still, the 6% hit to the share price Thursday and Friday, which erased $13B in enterprise value, probably exceeded the actual damage on an NPV basis.